Padra Serum Alborz Company was established in 2016 with the aim of producing plasma-derived products, especially ultra-safe plasma-derived products. In the first phase, the research and development phase of Padra Serum began with a focus on the antidote to snakebite and scorpion bites at Persis Gene Company. After completing the research and development and production stages of the prototype, the process of attracting private investors was completed and after attracting the investors, necessary measures were taken to design the production line according to the developed purification method.

In order to start production activities, Behnoud Pharmed Alborz was selected as a shared infrastructure and by the end of 2017, the installation and commissioning of the production line was completed and the first plasma refinery in Iran was put into operation.

In 2018, the industrial production of the first products was on the agenda and in October of the same year, the first series of ScoFab (scorpion antidote) product was produced. In the winter of 2019, the necessary approvals were obtained from the Food and Drug Administration of Iran, and in May 2019, the clinical study of this product was completed, which paved the way for entering the market and issuing a GMP certificate.

In 2021, after a successful clinical study, SnaFab product for the treatment of snake bites entered the country’s pharmaceutical market.

Padra Serum Alborz Company, since 2019, as the only domestic producer of snake and scorpion venom serums, observing the principles of cGMP, is responsible for providing more than 80% of the antidote required by the Ministry of Health and Medical Education of Iran.